I型干扰素通路抑制介导胰腺导管腺癌中MYC与KRAS依赖的NK和B细胞免疫逃逸
该研究利用Rosa26位点驱动人MYC适度表达的小鼠模型,模拟MYC三体状态,发现该水平MYC单独即可驱动胰腺神经内分泌肿瘤,并加速KRAS启动的前驱病变进展为转移性胰腺导管腺癌(PDAC)。表型分析揭示MYC与KRAS共同抑制I型干扰素通路,MYC-MIZ1复合物直接结合IRF5、IRF7、STAT1和STAT2基因启动子,去抑制该通路可促进B和NK细胞浸润肿瘤并延长生存。
要点
- 适度升高的MYC单独即可驱动胰腺神经内分泌肿瘤并加速KRAS启动的PDAC转移。
- MYC与KRAS协同抑制I型干扰素通路,MYC-MIZ1复合物直接结合IRF5、IRF7、STAT1、STAT2启动子。
- 去抑制I型干扰素调节基因可促进B和NK细胞浸润肿瘤并提高生存率。
核心结论
- MYC与KRAS通过抑制I型干扰素通路共同介导NK和B细胞免疫逃逸,促进PDAC进展。
- 恢复I型干扰素信号可能改善PDAC患者预后。
研究设计与样本
- 利用Rosa26位点驱动人MYC适度表达的小鼠模型,模拟MYC三体状态,研究胰腺表型。
主要发现
- 适度升高的MYC单独即可驱动胰腺神经内分泌肿瘤。
- 该水平MYC可加速KRAS启动的前驱病变进展为转移性PDAC。
- MYC与KRAS共同抑制I型干扰素通路。
- MYC-MIZ1复合物直接结合IRF5、IRF7、STAT1和STAT2基因启动子。
- 去抑制I型干扰素调节基因促进B和NK细胞浸润肿瘤并增加生存。
临床怎么用
- 恢复I型干扰素信号可能作为改善PDAC预后的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We used modestly elevated expression of human MYC, driven from the Rosa26 locus, to investigate the pancreatic phenotypes arising in mice from an approximation of MYC trisomy. We show that this level of MYC alone suffices to drive pancreatic neuroendocrine tumors, and to accelerate progression of KRAS-initiated precursor lesions to metastatic pancreatic ductal adenocarcinoma (PDAC). Our phenotype exposed suppression of the type I interferon (IFN) pathway by the combined actions of MYC and KRAS, and we present evidence of repressive MYC-MIZ1 complexes binding directly to the promoters of the genes encodiing the type I IFN regulators IRF5, IRF7, STAT1, and STAT2. Derepression of IFN regulator genes allows pancreatic tumor infiltration by B and natural killer (NK) cells, resulting in increased survival. SIGNIFICANCE: We define herein a novel mechanism of evasion of NK cell-mediated immunity through the combined actions of endogenously expressed mutant KRAS and modestly deregulated expression of MYC, via suppression of the type I IFN pathway. Restoration of IFN signaling may improve outcomes for patients with PDAC.This article is highlighted in the In This Issue feature, p. 747.
引用
- Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, et al. Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. Cancer Discov. 2020. PMID: 32200350. doi:10.1158/2159-8290.CD-19-0620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。